KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Total Debt (2016 - 2025)

Historic Total Debt for Biogen (BIIB) over the last 16 years, with Q4 2025 value amounting to $6.3 billion.

  • Biogen's Total Debt fell 14.3% to $6.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.3 billion, marking a year-over-year decrease of 14.3%. This contributed to the annual value of $6.3 billion for FY2025, which is 14.3% down from last year.
  • As of Q4 2025, Biogen's Total Debt stood at $6.3 billion, which was down 14.3% from $150.0 million recorded in Q2 2025.
  • In the past 5 years, Biogen's Total Debt registered a high of $6.9 billion during Q4 2023, and its lowest value of $150.0 million during Q2 2025.
  • For the 5-year period, Biogen's Total Debt averaged around $4.5 billion, with its median value being $6.3 billion (2022).
  • As far as peak fluctuations go, Biogen's Total Debt surged by 52866.58% in 2022, and later crashed by 925.89% in 2024.
  • Biogen's Total Debt (Quarter) stood at $999.1 million in 2021, then skyrocketed by 528.67% to $6.3 billion in 2022, then rose by 10.46% to $6.9 billion in 2023, then fell by 9.26% to $6.3 billion in 2024, then fell by 0.14% to $6.3 billion in 2025.
  • Its last three reported values are $6.3 billion in Q4 2025, $150.0 million for Q2 2025, and $6.3 billion during Q4 2024.